# Non-Apoptotic Programmed Cell Death: From Ultrastructural Characterization to Emerging Therapeutic Opportunities

## TL;DR

The paper explores non-apoptotic programmed cell death types like ferroptosis and necroptosis, highlighting their unique features and potential for new cancer and disease treatments.

## Contribution

The paper provides a detailed ultrastructural and molecular characterization of non-apoptotic PCD modalities and their therapeutic implications.

## Key findings

- Non-apoptotic PCD modalities have distinct ultrastructural and molecular features that differentiate them from apoptosis.
- Targeting these pathways offers new therapeutic strategies for cancer and neurodegenerative diseases.
- Understanding these pathways enables the development of biomarkers and precision medicine approaches.

## Abstract

What are the main findings?
Non-apoptotic programmed cell death comprises diverse modalities such as ferroptosis, necroptosis, pyroptosis, autophagy, paraptosis, autosis, and more, with each modality characterized by unique ultrastructural hallmarks and molecular signaling pathways that distinguish them from classical apoptosis.Comprehensive morphological characterization reveals distinct intracellular features for each non-apoptotic PCD modality, ranging from mitochondrial cristae reduction in ferroptosis to perinuclear space ballooning in autosis, facilitating their identification via advanced microscopy techniques.Non-apoptotic PCD pathways offer dual therapeutic potential: induction strategies can overcome apoptosis resistance in cancer therapy, while inhibition approaches provide cytoprotection in neurodegenerative diseases and myocardial injury.

Non-apoptotic programmed cell death comprises diverse modalities such as ferroptosis, necroptosis, pyroptosis, autophagy, paraptosis, autosis, and more, with each modality characterized by unique ultrastructural hallmarks and molecular signaling pathways that distinguish them from classical apoptosis.

Comprehensive morphological characterization reveals distinct intracellular features for each non-apoptotic PCD modality, ranging from mitochondrial cristae reduction in ferroptosis to perinuclear space ballooning in autosis, facilitating their identification via advanced microscopy techniques.

Non-apoptotic PCD pathways offer dual therapeutic potential: induction strategies can overcome apoptosis resistance in cancer therapy, while inhibition approaches provide cytoprotection in neurodegenerative diseases and myocardial injury.

What are the implications of the main findings?
Targeting non-apoptotic PCD pathways opens novel therapeutic avenues for apoptosis-resistant malignancies through pathway-specific nanomedicines and pharmacological modulators that selectively eliminate cancer cells while sparing normal tissue.Understanding ultrastructural hallmarks of non-apoptotic PCD enables precise mechanistic differentiation in disease models, supporting development of pathway-specific biomarkers and precision medicine approaches for cancer, neurodegeneration, and inflammatory diseases.The comprehensive characterization of non-apoptotic PCD modalities provides important templates to identify and manipulate these signaling pathways, potentially enabling the establishment of treatment strategies for a wide range of pathological conditions, from tumor immunity to tissue homeostasis.

Targeting non-apoptotic PCD pathways opens novel therapeutic avenues for apoptosis-resistant malignancies through pathway-specific nanomedicines and pharmacological modulators that selectively eliminate cancer cells while sparing normal tissue.

Understanding ultrastructural hallmarks of non-apoptotic PCD enables precise mechanistic differentiation in disease models, supporting development of pathway-specific biomarkers and precision medicine approaches for cancer, neurodegeneration, and inflammatory diseases.

The comprehensive characterization of non-apoptotic PCD modalities provides important templates to identify and manipulate these signaling pathways, potentially enabling the establishment of treatment strategies for a wide range of pathological conditions, from tumor immunity to tissue homeostasis.

Distinct forms of non-apoptotic programmed cell death (PCD) play a central role in human and animal health and their signaling cascades provide pharmacological targets for therapeutic interventions. Non-apoptotic modalities of programmed cell death include well characterized forms, such as ferroptosis, necroptosis, pyroptosis, autophagy, paraptosis, as well as newly characterized varieties, such as cuproptosis, disulfidptosis, and erebosis. Each pathway exhibits unique molecular signaling signatures, ultrastructural characteristics, and functional outcomes that distinguish them from classical apoptosis. While pharmacological targets in the signaling cascade are promising objectives for overcoming apoptosis resistance in cancer therapy, inhibition of cell death in the myocardium or nervous system is critical for cytoprotection. This review provides detailed characterization and schematic visualization of cellular and subcellular hallmarks for each non-apoptotic PCD modality, facilitating their morphological identification. Understanding these diverse pathways is crucial for developing innovative therapeutic interventions in cancer, neurodegeneration, and inflammatory diseases.